Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome.
about
Eosinophilic Granulomatosis With Polyangiitis With Thrombotic Microangiopathy: Is Simultaneous Systemic Lupus Erythematosus Associated With Clinical Manifestations?: A Case Report and Review of the LiteratureTherapeutic regulation of complement in patients with renal disease - where is the promise?A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injuryShiga Toxin (Stx) Classification, Structure, and FunctionHUS and TTP in ChildrenHemolytic uremic syndrome: toxins, vessels, and inflammationHaemolytic uraemic syndrome.Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature.The role of endothelial cell injury in thrombotic microangiopathy.Do complement factor H 402Y and C7 M allotypes predispose to (typical) haemolytic uraemic syndrome?Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?Shiga toxin pathogenesis: kidney complications and renal failure.Microparticle generation and leucocyte death in Shiga toxin-mediated HUS.Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS).Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control studyShigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.STEC-HUS, atypical HUS and TTP are all diseases of complement activation.Renal and neurological involvement in typical Shiga toxin-associated HUS.Circulating microRNAs in patients with Shiga-Toxin-producing E. coli O104:H4 induced hemolytic uremic syndrome.Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals.Hemolytic uremic syndrome: sound minds, sick kidneys.Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab.Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cellsQuiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy.Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndromeOutbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab.Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complementActivation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome.Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injuryEculizumab in secondary atypical haemolytic uraemic syndrome.Prioritization of biomarker targets in human umbilical cord blood: identification of proteins in infant blood serving as validated biomarkers in adultsComplement involvement in kidney diseases: From physiopathology to therapeutical targetingComplement Activation in Patients with Focal Segmental Glomerulosclerosis.Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.
P2860
Q26777537-427ECF2D-BCB3-4E98-9D53-6405B8E0ECF5Q26851705-462CC74D-31EB-44B7-A1BD-C7B11255D022Q26992169-E8635400-798A-4A86-9C5B-25573FA6418BQ27021676-44A7833A-7F78-4E09-84D9-1383092B1275Q27026538-9B4DAAD0-B91B-42D8-8B36-9225AD31BCA8Q28083347-B8D2A72E-D5AB-42B5-885B-9BBB3B3DF690Q30244707-A1106826-346A-444A-ABF3-FD0DED6CB4DBQ30249618-602F0A38-EC0E-49E2-AEA1-096F27BB4EB6Q33391882-C16FCB7F-6E43-424F-AAD4-9B029BFCDCE6Q33395682-06DA59C9-E918-4CFD-A30F-06867F827695Q33395774-138546B2-BE4B-4061-A7EF-AE74D612F2F7Q33397541-5AB359BD-ED8F-4192-A4A1-DF0811C7496AQ33399130-10163A04-C19D-405B-8F76-5367D3B7C58FQ33399468-0818397F-32AB-4033-8799-8551F22AE0FBQ33401572-22543DEF-7D38-45A1-8092-D54EB6EA1E4AQ33402456-C45C8918-7FBC-4F1C-8239-E3F3166510FCQ33402784-5FCA45B2-AE88-4D05-B893-6BB0F7039E04Q33403359-50A878E4-DDEC-4484-8B5E-81C7A4B324B6Q33403361-5935007F-0339-4557-A627-CB1CF3FB8E4DQ33403833-A393D7A0-98D9-45FC-88EC-AB5F24DE959AQ33404149-77C67AC1-BCAB-47BC-8851-53F4D9590DABQ33404151-F5FD9B72-A187-4BA0-8FAD-9F8FB907154BQ33404640-F8A55EE0-CE62-4331-B0CC-F8906EC6A702Q33407562-B40C0FFD-19C0-4586-8684-80241F06B7A9Q33407564-03D62133-3EBF-4033-A933-3CB0E9EEAFF8Q33407861-E7034221-804D-4A5E-8F69-A6591CDC738CQ33408183-1DD2EED6-58E8-4897-A2EB-1EA8DB890D2BQ33409030-7AC015AB-D138-4CA8-8004-F8A1770C7746Q33409878-642FC0DF-AEAE-474E-AF03-8434BC3E984DQ33411810-63A21EFC-DBFB-4312-9C5C-219C731008E1Q33413591-07F75C6A-813D-4544-971F-E5A0D973D114Q33420374-2A69F365-3127-4985-B6D1-109DD6E0D91DQ33423769-89C79D2B-FABF-45EA-8BC1-4C9613EFE353Q33426147-F2D5F83F-D69B-4DEE-97BD-F80012DE40C9Q33433630-351E3486-40A0-44F9-8339-3C4676F46525Q33620588-065A250E-7454-4685-964F-C31A30008603Q34248807-CF0C092A-A0E7-4683-A71D-2E8B25702DF0Q35567841-AEF24399-C266-490E-B577-20E4E59ACB36Q35763276-1112F900-C2B9-42F7-8D24-01FAC7AF3BE8Q37547496-4E97072D-C385-464B-B19B-9096A8E6CBA4
P2860
Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Alternative pathway of complem ...... ated hemolytic uremic syndrome
@nl
Alternative pathway of complem ...... ted hemolytic uremic syndrome.
@ast
Alternative pathway of complem ...... ted hemolytic uremic syndrome.
@en
type
label
Alternative pathway of complem ...... ated hemolytic uremic syndrome
@nl
Alternative pathway of complem ...... ted hemolytic uremic syndrome.
@ast
Alternative pathway of complem ...... ted hemolytic uremic syndrome.
@en
prefLabel
Alternative pathway of complem ...... ated hemolytic uremic syndrome
@nl
Alternative pathway of complem ...... ted hemolytic uremic syndrome.
@ast
Alternative pathway of complem ...... ted hemolytic uremic syndrome.
@en
P2093
P2860
P3181
P356
P1476
Alternative pathway of complem ...... ted hemolytic uremic syndrome.
@en
P2093
Cathy Hoffman
Christopher Smith
Erica Christen
Hillary Akana
Joshua M Thurman
Martin Lesser
Myriam Kline
Russell Marians
Susan Wood
V Michael Holers
P2860
P304
P3181
P356
10.2215/CJN.02730409
P407
P577
2009-10-09T00:00:00Z